Patriots' Cannon finally makes his NFL debut

At the beginning of November football fans and cancer haters everywhere celebrated as first-round draft pick Marcus Cannon hit the practice field for the New England Patriots for the first time since undergoing chemotherapy for non-Hodgkin's lymphoma.

Two weeks after that, the Patriots made the decision to move Cannon, an offensive tackle, to the active roster, his second major milestone in two weeks.

This past weekend, Marcus Cannon enjoyed what had to be the sweetest major milestone he's reached since overcoming cancer and being put into remission:

Cannon made his NFL debut in actual game. Monday Night Football no less.

Granted, Patriots coach Bill Belichick didn't put Cannon in until the team's final position of the fourth quarter, when the game was well in the hands of the Patriots, but that doesn't matter. What's important is that Cannon is back to playing football after facing cancer head-on, and for the time since his diagnosis, the big man's future looks bright.

Source: NFL.com

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap